Nature Biotechnology’s annual survey highlights academic startups that are, among other things, designing circular RNA therapeutics, tackling cancer with arenaviruses, creating psychedelics without the trip, editing genes and cells in vivo, harnessing the power of autoantibodies and editing the epigenome.
Enjoying our latest content?
Log in or create an account to continue
- Access the most recent journalism from Nature's award-winning team
- Explore the latest features & opinion covering groundbreaking research
or
Change history
28 December 2022
In the version of this article initially published, the name of Angelo Lombardo appeared incorrectly as Alberto Lombardo, and has now been amended in the HTML and PDF versions of the article.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Eisenstein, M., Garber, K., Landhuis, E. et al. Nature Biotechnology’s academic spinouts 2021. Nat Biotechnol 40, 1551–1562 (2022). https://doi.org/10.1038/s41587-022-01530-9
Published:
Issue date:
DOI: https://doi.org/10.1038/s41587-022-01530-9
This article is cited by
-
Meeting report on the round table discussions ‘epigenetics and society’ CLEPIC24
Epigenetics Communications (2025)
